Peptides
PEG-MGF (Pegylated MGF)
Also called PEG-MGF
PEG-MGF is promoted for muscle growth and recovery with less frequent dosing than ordinary MGF. The modification is intended to keep the peptide around longer, but neither longer exposure nor a reported twice-weekly schedule establishes better muscle gains in people.
Dosage & duration
One nonmedical proposal, not established use.
One nonmedical proposal
Reported use · unapproved regimen- Dose
- 125 or 200 mcg per dose
- How often
- Twice weekly; route not stated
- How long
- The poster asks about long-term use; no safe duration established
The post also discusses IGF-1 LR3. Do not interpret the answer as a safety study.
There is no verified safe cycle or evidence-backed rest-day advantage in these sources.
The longer-lasting pitch
Fewer injections is a claim about convenience
-
Why the PEG version
It is marketed as lasting longer than ordinary MGF.
-
The desired result
More muscle and faster recovery still need human evidence.
-
The product question
FDA flagged product-characterization and immune-response concerns.
Why people choose the PEG version
The draw is convenience: a product marketed as longer-lasting than MGF, sometimes paired with IGF-1 LR3. That is a reason people discuss it, not evidence that the combination adds muscle or shortens recovery.
What “longer-lasting” cannot tell you
Changing a peptide can alter exposure, but does not establish an effective human dose or the best day around training. FDA’s assessment identified no human exposure data for PEG-MGF products and flagged uncertainties about product characterization and immune reactions.
Do not borrow evidence from a scaffold
Some MGF studies use a local polymer carrier or study cells. Those are not the same product as circulating PEG-MGF in a purchased vial. The plot remains a timing illustration, not a measured recovery score.
Model details: PEG-MGF (Pegylated MGF) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 19.2 hours
- Absorption half-life assumed
- 4.8 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (4.8 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- PEG size, conjugation and product identity are not specified. A PEG-containing delivery scaffold does not establish the circulation kinetics of a PEG-MGF conjugate.
- FDA bulk-substance review: PEG-MGF
The PEG-MGF entry states FDA had not identified human exposure data via any route.
peg-mgf-relative-timing-2026-10 · version 1
Common questions
Is PEG-MGF proven better than MGF?
No human comparison in the checked sources establishes better growth or recovery.
Can it be run indefinitely?
A reported duration does not establish long-term safety; FDA identifies major human-data gaps.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main goal
- Reported motivations rather than established human benefits.
- Reason for PEG
- Not proof of a particular human half-life or schedule.
- Discussed pairing
- A reported pairing is not a validated combination.
- 1. FDA — PEG-MGF safety assessment
PEG-MGF entry: no identified human exposure data; impurity, characterization and immune-response concerns.
- 2. FDA bulk-substance review: PEG-MGF
The PEG-MGF entry states FDA had not identified human exposure data via any route.
- 3. MGF E-domain delivery in a polymeric scaffold
Original mouse cardiac-injury work used localized peptide delivery from polymeric microstructures; PEG-based carrier is not evidence for a generic circulating PEG-MGF drug.
- 4. IGF1Ec and isolated E-peptide comparison
Cell study demonstrates that isolated E-domain peptide and intact IGF1Ec have different functions.
Related compounds and examples
Related compounds
MGF (Mechano Growth Factor)
MGF for muscle recovery and growth: reported dose claims, workout timing and the difference from PEG-MGF.
IGF-1 DES
IGF-1 DES: workout and local-growth claims, reported amounts and how it differs from LR3.
IGF-1 LR3
IGF-1 LR3 for muscle growth: reported doses and cycles, DES comparison and glucose-related concerns.